362 related articles for article (PubMed ID: 27106699)
1. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699
[TBL] [Abstract][Full Text] [Related]
2. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
5. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
6. The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Cho BS; Kim YJ; Cho SG; Kim SY; Eom KS; Kim HJ; Lee S; Min CK; Kim DW; Lee JW; Min WS; Kim CC
Int J Hematol; 2007 Jun; 85(5):446-55. PubMed ID: 17562624
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
8. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
10. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
[TBL] [Abstract][Full Text] [Related]
12. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
13. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
[TBL] [Abstract][Full Text] [Related]
14. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
16. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Park SS; Jeon YW; Min GJ; Park S; Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Lee S; Kim HJ; Min CK; Cho SG; Lee JW; Kim YJ
Biol Blood Marrow Transplant; 2019 Jan; 25(1):63-72. PubMed ID: 30103018
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Lee KH; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Hwang HJ; Jung AR; Kim SH; Yun SC; Shin HJ
Blood; 2011 Sep; 118(9):2609-17. PubMed ID: 21715313
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.
Schneidawind D; Federmann B; Buechele C; Helwig A; Schmohl J; Vogel W; Faul C; Kanz L; Bethge WA
Ann Hematol; 2016 Jan; 95(1):115-124. PubMed ID: 26411736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]